Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: Results from the 14-year follow-up of a large cohort from Southern Germany

Circulation

Volumn 110, Issue 14, 2004, Pages 1903-1908

  Koenig, Wolfgang ^a   Khuseyinova, Natalie ^a   Löwel, Hannelore ^b,c   Trischler, Gerlinde ^a   Meisinger, Christa ^b,c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c KLINIKUM AUGSBURG   (Germany)

Author keywords

Coronary disease; Epidemiology; Inflammation; Prognosis; Risk factors

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GERMANY; HUMAN; INCIDENCE; INFLAMMATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; COHORT STUDIES; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; GERMANY; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PHOSPHOLIPASES A; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 4944261232     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000143377.53389.C8     Document Type: Article

References (30)

1. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-897.
2. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
3. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C-77C.
4. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
5. Greenland P, Smith SC, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863-1867.
6. Koenig W, Rosenson RS. Emerging risk factors: acute phase reactants. In: Lowe GDO, Danesh J, guest editors. Risk factors for coronary disease. Semin Vasc Med. 2002;2:417-428.
7. Pearson TA, Mensah GA, Alexander WR, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
8. Koenig W, Löwel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in Southern Germany. Circulation. 2004;109:1349-1353.
9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
10. 2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol. 2003;14:347-352.
11. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57-68.
12. 2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002;2:17-22.
13. Stafforini DM, Elstad MR, McIntyre TM, et al. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem. 1990;265:9682-9687.
14. Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999;261:511-514.
15. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909-2917.
16. 2 inhibition: a novel, non-lipid lowering strategy for atherosclerosis therapy. Farmaco. 2001;56:45-50.
17. 2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413-419.
18. WHO-MONICA Project Principal Investigators. The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol. 1988;41:105-114.
19. WHO MONICA Project. WHO MONICA project: objectives and design. Int J Epidemiol. 1989;18(suppl 1):29-37.
20. Loewel H, Lewis M, Hoermann A, Keil U. Case finding, data quality aspects and comparability of myocardial infarction registers: results of a south German register study. J Clin Epidemiol. 1991;44:249-260.
21. Hense HW, Filipiak B, Döring A, et al. Ten-year trends of cardiovascular risk factors in the MONICA Augsburg region in southern Germany: results from 1984/1985, 1989/1990, and 1994/1995 surveys. CVD Prev. 1998;1:318-327.
22. Koenig W, Sund M, Döring A, et al. Leisure-time physical activity but not work-related physical activity is associated with decreased plasma viscosity: results from a large population sample. Circulation. 1997;95:335-341.
23. Hutchinson WL, Koenig W, Fröhlich M, et al. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem. 2000;46:934-938.
24. 2 as an independent predictor of coronary heart disease: West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148-1155.
25. 2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302-1306.
26. Satoh K, Imaizumi T, Yoshida H, et al. Platelet-activating factor acetylhydrolase in plasma lipoproteins of healthy men and women. Clin Chim Acta. 1991;202:95-103.
27. Imaizumi T, Stafforini DM, Yamada Y, et al. The fate of platelet-activating factor: PAF acetylhydrolase from plasma and tissues. In: Gross R, ed. Advances in Lipobiology. Greenwich, Conn: JAI Press; 1996;1:141-162.
28. Kosaka T, Yamaguchi M, Miyanaga K, et al. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin Chim Acta. 2001;312:179-183.
29. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837-842.
30. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479-487.